

Biphasic Effects of Naloxone in the Rats Receiving Morphine Overdose A Place Preference Study

Sara Karimi^a, Manizheh Karami^a, Homeira Zardooz^b,
Seyed Hassan Salimi^c and Hedayat Sahraei^{d*}

^aDepartment of Biology, Faculty of Sciences, Shahed University, Tehran, Iran. ^bDepartment of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ^cDepartment of Psychology, School of Medicine, Baqiyatallah (A.S.) University of Medical Sciences, Tehran, Iran. ^dNeuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Abstract

Downward phase of dose-response morphine converted U shape curve was chosen as a base for investigating the effects of different doses of naloxone (0.05-0.4 mg/Kg) on morphine reward/aversion properties using place preference method.

First, male Wistar rats (200-220 g) were received morphine (1-7.5 mg/Kg) for place conditioning and marginal dose of morphine (5 mg/Kg) calculated by GraphPad software. In the next part, the animals received different naloxone challenge doses (0.05-0.4 mg/Kg; IP) on the test day. Animals' behavior was monitored using a video camera during the test session. Time spent in each compartment was calculated as the main sign of drug seeking behavior. In addition, numbers of rearing and sniffing as well as locomotion activity for each animal were counted as important dopamine-dependent behavioral signs. More over, the total compartment crossing by each animal as the sign of decision making was also counted.

Our results indicated that naloxone showed biphasic effects on the appearance of morphine-induced place preference. The antagonist potentiates the expression of morphine-induced place preference on the dose of 0.05 and 0.4 mg/Kg while inhibits the morphine effect on the dose of 0.1 mg/Kg. On the other hand, the total animal sniffing, rearing, locomotion, and compartment entering were not significantly changed among the groups.

It could be concluded that the inhibition of opioid receptors may enhance or inhibit the expression of morphine reward according to the naloxone dose, which in turn indicate the influence of several opioid receptor in this regard. In addition, opioid receptor blocking did not enhance the signs of drug seeking behavior linked to the activity of mesolimbic dopamine system.

Keywords: Morphine; Naloxone; Sniffing; Rearing; Locomotion; Conditioned; Place preference; Rat.

Introduction

It is now clear that mesolimbic dopamine system which originates from ventral tegmental

area (VTA) of the midbrain and projects mainly to the nucleus accumbens (NAcc), is the major target for morphine reward (1, 2). Studies by Johnson and North (3) have indicated that the inhibitory influence of gamma-aminobutyric acid-ergic (GABAergic) interneurons on VTA dopaminergic neurons is removed by mu-opioid

* Corresponding author:

E-mail: h.sahrei@bmsu.ac.ir

receptors activation (by morphine-for example) which actually leads to an increase in extra-cellular dopamine concentrations in the targets of these neurons in nucleus accumbens (3, 4, 5).

One reliable and relatively simple method for studying opioid reward is the conditioned place preference method (6). Previous studies have indicated that opioids can induce place preference in different animal models (6). Studies indicated that in this method, opioid dose-response curve has an inverted U shape as the dose of the drug increased gradually (For rev see: 7). Activation of different opioid receptors in the VTA is considered as the main reason for such inverted U shape dose-response curve (8). Opioid place preference consists of two distinct components, namely acquisition and expression (6, 9). Understandings of the mechanisms involved in each component were the aim of intense investigations during past years. For example, it is now clear that opioid place conditioning is based on dopamine receptor activation in nucleus accumbens (10, 11, 12). In addition, several neurotransmitters in different parts of central nervous system have also been shown to be involved both in the acquisition and expression of opioid place preference (See 6 for Rev). Interestingly, it is not clear if opioid receptors are also involved in the expression of opioid place conditioning or not. In order to answer this question, the present study was designed. For this reason, we first determined morphine (as typical opioid) dose-response curve, then calculated the downward point of the curve and finally the effect of naloxone (as opioid receptor antagonist) on this point was studied. Naloxone which was chosen as the antagonist can inhibit different opioid receptors in different doses i.e., in lower doses it inhibits mu-opioid receptors and in higher doses it inhibits delta-opioid and kappa-opioid receptors (13). If the antagonist could change the downward point, one can conclude that opioid receptors are also involved in the expression of morphine and other opioid place preference.

Experimental

The male Wistar rats (250 ± 20 g, Pasteur Institute, Tehran, IRAN) were housed in groups

of 4 rats per cage in a 12/12 h light-cycle (lights on, at 07.00 a.m.), with *ad libitum* food and water available. All experiments were conducted in accordance with standard ethical guidelines and approved by the local ethical committee (The Baqiyatallah (A.S.) University of Medical Committee on the Use and Care of Animals, 81/021, July 10, 2002).

Drugs

Morphine sulfate (TEMAD Co., Tehran, IRAN) and Naloxone hydrochloride (Sigma, USA) were dissolved in sterile saline and were injected subcutaneously in a volume of 1 mL/Kg. For evaluating the effects of morphine on place preference behavior, different doses of morphine (1, 2.5, 5, and 7.5 mg/Kg) were injected into the animals.

Apparatus

A two compartment conditioned place preference (CPP) apparatus ($30 \times 60 \times 30$ cm) was used. The apparatus was made of wood. Both compartments were identical in size (the apparatus was divided into two equal-sized compartments by means of a white removable wall) and shading (both were white), but distinguishable by texture and olfactory cue. To provide the tactile difference between the compartments, one of them was chosen with a smooth floor, while the other one had a white nylon mesh floor. A drop of menthol was placed at the corner of the compartment with a textured (nylon mesh) floor to provide the olfactory difference between the compartments. Their walls were differently black-striped (one compartment horizontal and the other one vertical) on their sides. In this apparatus, rats showed no consistent preference for either compartment (14). A video camera located 120 cm above the apparatus, recorded all animals' behavior during the experiments. The video types then were observed by an observer which was unfamiliar to the experiments.

Experimental procedure

Each conditioning session consists of 5 days. On the first day of experiments, each rat was placed separately into the apparatus for 10 min, with free access to all compartments and the time spent by rats in each compartment was

Table 1. Effects of different doses of morphine on the mesolimbic dopamine system related behaviors (number of sniffing, rearing and locomotion) and total compartment entering in rats on the test day. Data are shown as mean \pm SEM for 6-8 rats.

| Morphine (mg/Kg) | Sniffing (No./10 min) | Rearing (No./10 min) | Locomotion (No./10 min) | Compartment entering (No./10 min) |
|------------------|-----------------------|----------------------|-------------------------|-----------------------------------|
| 0 | 11 \pm 3 | 8 \pm 2 | 12 \pm 3 | 7 \pm 3 |
| 1 | 14 \pm 4 | 13 \pm 3 | 18 \pm 5 | 11 \pm 4 |
| 2.5 | 12 \pm 3 | 10 \pm 4 | 14 \pm 4 | 11 \pm 3 |
| 5 | 7 \pm 4 | 7 \pm 3 | 12 \pm 4 | 7 \pm 3 |
| 7.5 | 9 \pm 3 | 8 \pm 3 | 9 \pm 4 | 8 \pm 3 |

measured. In the second phase which consisted of a 3-day schedule, animals received three trials in which they experienced the effects of the morphine while confined in one compartment for 45 min and then three trials in which they experienced the effects of saline while confined in the other compartment for 45 min. Access to the other compartments was blocked on these days. On the 5th day (the preference test day) the partition was removed, and the rats could access the entire apparatus. The mean time for each rat spent in either compartment during a 10 min period was determined as the preference criterion. Naloxone was injected 30 min before the tests in the preference test day.

Statistical analysis

Data were given as the mean \pm SEM for 6-8 animals. One-way analysis of variance (ANOVA) followed by Tukey's test were performed to assess specific group comparisons. Differences with $p < 0.05$ were considered statistically significant.

Results and Discussion

Morphine place conditioning behavior in the rats

Figure 1 shows the effects of different doses of morphine on place conditioning behavior. Morphine administration can dependently induce a clear place conditioning dose with maximum effect on 2.5 mg/Kg of the drug [F (5, 38) = 4.352, $p < 0.001$]. In addition, non-linear regression calculation indicated that half-maximal effective dose (ED50) of morphine is 1.88 mg/Kg \pm 0.02. We calculated the opposite point of ED50 on the dose-response curve as downward point for morphine effect (4.3 mg/Kg). According to this

calculation, 5 mg/Kg of morphine was chosen as downward point for the rest of the experiments (Figure 1). On the other hand, the number of compartment entering, locomotion, rearing and sniffing is reduced while the dose of morphine is increased (i.e. a clear drug-seeking behavior) (Table 1, [F (5, 38) = 1.343, $p < 0.1$] for sniffing, [F (5, 38) = 1.003, $p < 0.1$] rearing, [F (5, 38) = 0.992, $p < 0.1$] locomotion, and [F (5, 38) = 1.21, $p < 0.1$] compartment entering).

Effects of different doses of naloxone on the expression of downward morphine dose

In the second part of the experiments, different doses of naloxone (0.05, 0.1, 0.2 and 0.4 mg/Kg; s.c.) were administered to the animals which received downward morphine (5 mg/Kg; s.c.) in the conditioning days. Our results showed that the administration of naloxone for inhibition of opioid receptors on the expression day naloxone in doses of 0.05 and 0.4 mg/Kg increased the expression of morphine place preference (Figure 2, [F (5, 39) = 6.78, $p < 0.0001$]). However, the antagonist at dose of 0.1 mg/Kg induced a significant place aversion instead of place preference (Figure 2). Measurement of sniffing, rearing, locomotion and compartment entering also showed that these factors did not changed among the groups (Table 2, [F(5, 39) = 0.56, $p < 0.1$] for sniffing, [F(5, 39) = 0.988, $p < 0.1$] rearing, [F (5, 39) = 1.87, $p < 0.1$] locomotion, and [F(5, 39) = 0.99, $p < 0.1$] compartment entering).

Discussion

Our results indicated that the inhibition of opioid receptors by naloxone could potentiate the expression of morphine-induced place

Table 2: Effects of different doses of naloxone (0.05, 0.1, 0.2, 0.4 mg/Kg; SC) on the mesolimbic dopamine system-related behaviors (number of sniffing, rearing and locomotion) and total compartment entering in rats on the test day. Data are shown as mean \pm SEM for 6-8 rats.

| Naloxone (mg/Kg) | Sniffing (No./10 min) | Rearing (No./10 min) | Locomotion (No./10 min) | Compartment entering (No./10 min) |
|------------------|-----------------------|----------------------|-------------------------|-----------------------------------|
| 0 | 14 \pm 3 | 11 \pm 2 | 11 \pm 3 | 14 \pm 3 |
| 0.05 | 11 \pm 3 | 10 \pm 4 | 15 \pm 6 | 12 \pm 4 |
| 0.1 | 11 \pm 3 | 11 \pm 4 | 12 \pm 4 | 13 \pm 5 |
| 0.2 | 12 \pm 3 | 12 \pm 4 | 12 \pm 3 | 14 \pm 3 |
| 0.4 | 11 \pm 3 | 13 \pm 3 | 12 \pm 3 | 14 \pm 4 |

preference conditioning in doses of 0.05 and 0.4 and reverses the opioid effect in dose of 0.1 mg/Kg. It is important to notify that the similar results obtained for low and high doses of naloxone may not have similar base and mechanism(s). On the other hand, numbers of sniffing, rearing, and locomotion as indicators of mesolimbic dopamine-system activity (15-20) were not different from the control group. Results obtained from our experiments indicated that naloxone in low and high doses exacerbate and in medium dose (*e.g.*, 0.1 mg/Kg) reversed the expression of morphine CPP. These findings indicated the involvement of opioid receptors in the phenomenon. In agreement with previous studies, our results indicated that morphine can induce place preference in rats and mice (For review: 6, 21, 22). However, our results indicated that the maximum effect on place preference was achieved in dose of 2.5 mg/Kg which is also reported in previous studies (6). Previous studies also indicated that opioid receptor inhibition reduced the acquisition and expression of place preference induced by opioids (6, 23, 24, 25, 26, 27). On the other hand, in the previous studies, the effects of antagonists were observed on the doses of opioids which induced maximum response (6, 24, 27); this response was achieved at doses in which probably just one type of the opioid receptors was occupied by the opioid (6, 13, 24), though, in the present study, we proposed that by blockade of opioid receptors when downward shift of morphine dose-response curve was begun, dissociation the influence of different opioid receptors could be achieved on the morphine place preference. The special point here is that the receptor shifting may be occurring. In agreement with our proposal, studies have shown that agonists of

kappa opioid receptors can induce place aversion in mice (6, 23, 27). It would have been quite normal that if these receptors were inhibited (by naloxone for example), the effects of other opioid receptors could have been observed. As the rewarding effects of opioids are related to mu-opioid receptor activation (23), in the present study, one can conclude that inhibition of the other opioid receptors is the main reason for augmentation of the expression of morphine-induced place preference which was observed for high naloxone (0.4 mg/Kg) dose. It seems that the reason of potentiating the expression of morphine-induced place preference by low dose of naloxone (*e.g.* 0.05 mg/Kg) is different and needs another explanation. However, it is now clear that mu-opioid receptors can either inhibit or activate the enzyme adenylate cyclase (AC) in the plasma membrane of the target cells (13, 28), which in turn, decreases or increases intracellular concentration of the cyclic adenosine monophosphate (cAMP), respectively (13, 28). Although the population of the last kind of receptors is much lower, activation of this kind of opioid receptors can unfortunately mask the real potential of the second (28). Therefore, inhibition of these receptors by low doses of opioid receptor antagonists can increase morphine antinociception as well as reward potency (13, 29, 30). Our explanation for the effect of low dose of naloxone is that the drug may inhibit the mu-opioid receptors which activate AC and unmasks the real role of the main mu-opioid receptor population which inhibit AC (13). So, the potentiation of the expression of morphine-induced place preference was observed as a result.

One important finding from our results is that the effects were not due to a change in




Figure 1. The effects of different doses of morphine on the place preference paradigm behavior. Animals received morphine (1, 2.5, 5 and 7.5 mg/Kg; SC) during conditioning session and were examined in the test day in drug free state. Non-linear regression was also applied for the calculation of ED50 and the opposite point was calculated as downward point. Data are shown as mean \pm SEM for 6-8 rats, * p < 0.05, ** p < 0.01 different from the saline control group.




Figure 2. The effects of different doses of naloxone (0.05, 0.1, 0.2 and 0.4 mg/Kg; SC.) on the expression of morphine-induced place preference when challenged with the downward point dose of morphine (5 mg/Kg). Data are shown as mean \pm SEM for 6-8 rats, * p < 0.05, ** p < 0.01 different from the saline control group.

dopamine-mesolimbic system activity as the behaviors related to the activities of mesolimbic dopamine system (dopamine related behaviors) such as sniffing, rearing and locomotion did not change for the experimental and control groups. In addition, total compartment entering as an indicator of decision making was not changed which indicated that the behaviors related (at least in part) to the other central nervous system regions (i.e. frontal cortex) was not affected by our intervention.

In conclusion, our results indicated that the expression of morphine place preference may be related to the mu-opioid receptors activity. Besides, the receptors may also be similar to opioid receptors that inhibit AC rather than those activate the enzyme.

Acknowledgment

This work was supported by the grant from the Investigation Department of Sciences Faculty of Shahed University.

References

- (1) Spanagel R and Weiss F. The dopamine hypothesis of reward: past and current status. *Trends in Neuroscience* (1999) 22: 521-7.
- (2) Wise RA. Drug-activation of brain reward pathways.

- (3) Johnson SW and North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. *J. Neurosci.* (1992) 12: 483-9.
- (4) Di Chiara G and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc. Natl. Acad. Sci. USA.* (1988) 85: 5274-8.
- (5) Pontieri FE, Tanda G and Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the «shell» as compared with the «core» of the rat nucleus accumbens. *Proc. Natl. Acad. Sci. U S A.* (1995) 92: 12304-12308.
- (6) Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. *Addiction Biology* (2007) 12: 227-462.
- (7) Koob GF. Drugs of abuse: Anatomy, pharmacology, and function of reward pathways. *Trends Pharmacol. Sci.* (1992) 13: 177-84.
- (8) Kalivas PW, Duffy P and Eberhardt H. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. *J. Pharmacol. Exp. Ther.* (1990) 253: 858-66.
- (9) Tzschentke TM. Measuring reward with the conditioning place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. *Prog. Neurobiol.* (1998) 56: 613-72.
- (10) Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. *Drug Alcohol Depend.* (1995) 38: 95-137.
- (11) Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. *Eur. J. Pharmacol.* (1999) 375: 13-30.

- (12) Vindenes V, Pettersen BS, Gottas A, Christiansen NL, Boix F and Morland J. Different Effects on Dopamine Release in Nucleus Accumbens in Mice by the Morphine Metabolites Morphine-6-Glucuronide and Morphine-3-Glucuronide. *Basic Clin. Pharmacol. Toxicol.* 2009 (InPress).
- (13) Gutstein HB and Akil H. Opioid analgesics. In: Hardman JG, Limbird LE and Goodman Gilman A. (eds.) *Goodman and Gilman's the Pharmacological Basis of Therapeutics*. 10th ed. McGraw-Hill, New York (2001) 569-619.
- (14) Wise, R.A., 2008. Dopamine and reward: the anhedonia hypothesis 30 years on. *Neurotox Res* 14, 169-183.
- (15) Karami M, Zarrindast MR, Sepehri H and Sahraei H. Role of nitric oxide in the rat hippocampal CA1 area on morphine-induced conditioned place preference. *Eur. J. Pharmacol.* (2002) 449: 113-19.
- (16) Blanchard DC and Blanchard RJ. Cocaine potentiates defensive behaviors related to fear and anxiety. *Neurosci. Biobehav. Rev.* (1990) 23: 981-991.
- (17) Blanchard RJ, Dulloog L, Kaawaloa N and Nishimura O. Acute cocaine effects on stereotypy and defense: an ethoexperimental approach. *Neurosci. Biobehav. Rev.* (1998) 23: 179-188.
- (18) Campbell A, B.R., Cremens C, Teicher MH, Marsh E., NS., K., 1989. Bromocriptine antagonizes behavioral effects of cocaine in the rat. *Neuropsychopharm* 2, 209-224.
- (19) Welker WI. Analysis of sniffing of the albinor rat. *Behavior* (1964) 22: 223-244.
- (20) Youngentob SL, Mozell MM, Sheehe PR and Hornung DE. A quantitative analysis of sniffing strategies in rats performing odor detection tasks. *Physiol. Behav.* (1987) 41: 59-69.
- (21) Tolliver BK and Sharp FR. Suppression of C-fos induction in the nucleus accumbens prevents acquisition but not expression of morphine-conditioned place preference. *Eur. J. Neurosci.* (2000) 12: 3399-3406.
- (22) Tsuji M, Matsumiya T, Nagase H, Narita M, and Suzuki T. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. *Life Sci.* (2001) 68: 1717-1725.
- (23) Contarino A, Matthes HW, Koob GF, Kieffer BL and Gold LH. Lack of reward and locomotor stimulation induced by heroin in mu-opioid receptor-deficient mice. *Eur. J. Pharmacol.* (2002) 446: 103-109.
- (24) Herzig VSW. Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats. *Neurosci. Lett.* (2005) 374: 119-123.
- (25) Herzig VSW. Repeated-testing of place preference expression for evaluation of anti-craving-drug effects. *Amino Acids* (2005) 28: 309-317.
- (26) Powell KJ, Jhamandas A, Olmstead MC, Beninger RJ and Jhamandas K. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. *J. Pharmacol. Exp. Ther.* (2002) 300: 588-596.
- (27) Salamone JD. The behavioral neurochemistry of motivation: methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. *J. Neurosci. Methods* (1996) 64: 137-149.
- (28) Sharma SK, Klee WA and Nirenberg M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. *PNAS* (1995) 72: 302-336.
- (29) Yeh YC, Lin TF, Wang CH, Wang YP, Lin CJ and Sun WZ. Effect of combining ultralow-dose naloxone with morphine in intravenous patient-controlled analgesia: the cut-off ratio of naloxone to morphine for antiemesis after gynecologic surgery. *J. Formos. Med. Assoc.* (2008) 107: 478-484.
- (30) Abul-Husn NS, Sutak M, Milne B and Jhamandas K. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists. *Br. J. Pharmacol.* (2007) 151: 877-887.